Answers are grounded in this paper and cite their sources.
Smoothened inhibitors represent the first class of targeted drugs approved for use in advanced and metastatic basal cell carcinoma. For many patients with limited treatment options, this drug class has led to significant clinical improvements, but is not without side effects. In this review, we outline the basic mechanism of smoothened inhibitors and the most commonly observed cutaneous and extracutaneous side effects. We also highlight possible mechanisms for these adverse events and current management strategies.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: